PSN
PSN Urges FG to Declare Pharmaceutical Insecurity a National Security Threat, Proposes Federal Drug Agency
The Pharmaceutical Society of Nigeria has urged the Federal Government to declare pharmaceutical insecurity a national security threat, citing drug diversion, counterfeit medicines and illicit trafficking. It also proposed a Federal Drug Management Agency to strengthen government oversight of medicine procurement and distribution.
The Pharmaceutical Society of Nigeria (PSN) has called on the Federal Government to declare pharmaceutical insecurity a national security threat, warning that drug diversion, illicit trafficking and counterfeit medicines pose growing risks to public health and national security.
The Society made the call during the opening ceremony of its 99th Annual National Conference, tagged PSN-IJELE 2026, held at the International Convention Centre in Awka, Anambra State.
Speaking at the event on 3 November 2026, PSN President, Pharm. Ayuba Ibrahim Tanko, argued that the management and distribution of medicines should remain under effective government oversight because of their implications for public health, regulatory accountability and national security.
He expressed concern that the increasing influence of private interests in the pharmaceutical supply chain could weaken public control over medicine procurement, distribution and dispensing.
According to the Society, uncontrolled drug markets and the diversion of medicines into illicit channels undermine efforts to maintain a safe and properly regulated pharmaceutical distribution system.
PSN Questions Private-Sector Control of Public Medicine Supply
A major concern raised by the Society centres on the Federal Government's proposed arrangement involving Medipool, an approved National Group Purchasing Organisation (GPO) intended to improve the procurement and distribution of medicines.
The Federal Executive Council approved Medipool in May 2025, while the Federal Ministry of Health and Social Welfare signed a Memorandum of Understanding with the organisation on 16 February 2026 to operationalise the arrangement, initially involving the Basic Health Care Provision Fund and federal tertiary hospitals.
Although acknowledging the potential benefits of pooled procurement, including reduced medicine costs, fewer stock-outs, improved transparency and support for local pharmaceutical manufacturers, PSN questioned the legal and institutional framework governing the arrangement.
The Society argued that transferring significant responsibilities across the pharmaceutical supply chain to a private operator could weaken existing collaboration between government and the country's pharmaceutical regulatory agencies.
It specifically identified the Pharmacy Council of Nigeria (PCN), the National Agency for Food and Drug Administration and Control (NAFDAC), and the National Drug Law Enforcement Agency (NDLEA) as critical institutions whose regulatory responsibilities must remain protected.
PSN maintained that government institutions benefit from established inter-agency cooperation in inspections, information sharing, enforcement and accountability, particularly in the management of controlled medicines.
It warned that placing a private commercial operator between government institutions and regulatory agencies could complicate these relationships.
PSN Proposes Federal Drug Management Agency
As part of its proposed reforms, the Society called for the establishment of a Federal Drug Management Agency, supported by legislation, to provide a transparent and accountable framework for the procurement, distribution and management of medicines across federal health institutions.
The proposed agency would strengthen public-sector management of pharmaceutical resources, protect procurement funds and improve continuity of medicine supply.
PSN also advocated for a stronger statutory framework for the Drug Revolving Fund (DRF), arguing that existing arrangements require better legal protection against diversion and administrative interference.
The Society further proposed that the Federal Drug Management Agency and the Drug Revolving Fund should serve as the central procurement and supply platform for public health institutions.
Under its proposed arrangement, Medipool could still participate in pooled price negotiations or operate as a framework supplier, provided it is competitively selected and does not exercise exclusive control over the supply chain.
The Society clarified that its opposition was not directed at the concept of group purchasing itself but at the structure, legality and operational framework of the proposed arrangement.
Pharmacists Call for Replacement of Open Drug Markets
Beyond concerns about public-sector procurement, PSN urged the Federal Government to replace unregulated open drug markets with licensed Coordinated Wholesale Centres (CWCs) operating under appropriate regulatory supervision.
The proposed centres are expected to strengthen accountability, improve traceability and ensure that medicines move through authorised distribution channels.
The Society also called for the integration of community pharmacists into Nigeria's national security architecture, proposing that more than 10,000 community pharmacists be recognised as frontline health and security stakeholders.
Under this proposal, community pharmacists would contribute to identifying and reporting suspicious pharmaceutical activities within their communities.
PSN also recommended establishing a Presidential Committee on the Pharmaceutical Sector to coordinate policy interventions and strengthen collaboration among government institutions, regulators and professional stakeholders.
Drug Diversion and Insecurity: PSN Calls for Stronger Enforcement
The Society linked pharmaceutical insecurity to the diversion and abuse of controlled medicines, particularly substances such as tramadol and pentazocine.
It warned that medicines diverted from legitimate supply channels could find their way into criminal networks, potentially contributing to banditry, violent extremism and other security challenges.
The Society also highlighted the need for stronger enforcement against counterfeit and substandard medicines, arguing that weaknesses in medicine distribution systems create opportunities for illicit operators.
It called for a special fund to combat illicit financial flows in healthcare, proposing that one per cent of assets seized from drug trafficking be dedicated to strengthening the enforcement activities of PCN and NAFDAC.
The proposed funding mechanism would support regulatory enforcement and rehabilitation activities.
What the Proposal Means for Nigeria's Pharmaceutical Sector
The PSN's position brings renewed attention to an important policy question: how can Nigeria improve the efficiency and affordability of medicine procurement without weakening public accountability and pharmaceutical regulation?
Group purchasing arrangements can potentially improve procurement efficiency through demand aggregation, stronger purchasing power and more coordinated supply systems.
However, their effectiveness also depends on transparent procurement processes, clearly defined institutional responsibilities, appropriate regulatory oversight and effective accountability mechanisms.
Nigeria's Health Products Supply System Policy, Second Edition, 2026, issued by the Federal Ministry of Health and Social Welfare, recognises Medipool within the country's health products supply architecture as a procurement mechanism operating through a public-private partnership.
This provides an important policy context for the ongoing debate, particularly as stakeholders consider how private-sector participation should complement public-sector responsibilities.
For pharmacists, the discussion has implications beyond procurement arrangements. It concerns the integrity of medicine distribution, professional oversight, controlled medicines management, supply-chain traceability and the availability of quality-assured medicines to patients.
The proposed Federal Drug Management Agency, if adopted and supported by appropriate legislation, could represent a significant institutional change in how medicines are procured and distributed across federal health facilities.
However, its effectiveness would depend on its legal mandate, governance structure, funding arrangements and relationship with existing regulatory and supply-chain institutions.
As the debate continues, the Federal Government faces the challenge of balancing procurement efficiency with the need to maintain a transparent, accountable and properly regulated pharmaceutical supply system.
For PSN, safeguarding Nigeria's medicine supply chain is not merely an administrative or commercial issue but an essential component of protecting public health and national security.